Heart failure & cardiomyopathies
Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement
Main finding · Composite of acute myocardial infarction, stroke, all-cause mortality, and acute CHFResult — go to the resultHazard ratio 0.79Authors' conclusion
Among CHF patients undergoing TAVR, SGLT2i use was not associated with a reduced risk of the primary composite outcome at 6-months and 1-year intervals.
Study context
- Population
- Patients ≥18 years old with congestive heart failure (CHF) who underwent a transcatheter aortic valve replacement (TAVR) procedureCHF patients undergoing TAVR identified, of whom 2,464 were on SGLT2 inhibitors therapy, 2,039 patients in each group after propensity score matching
- Participants
- 21,828 patients
- Exposure
- SGLT2 inhibitors vs standard care in CHF patients undergoing TAVR
- SGLT2 inhibitorsn = 2,039
- Standard caren = 2,039reference
- Outcome
- Composite of:
- Acute myocardial infarction
- Stroke
- All-cause mortality
- Acute CHF
- Follow-up
- 6 months
Methodological detailspropensity score matching, deidentified, aggregate patient data from the TriNETX research network
- Propensity score matching
- Deidentified, aggregate patient data from the TriNETX research network
Main finding
As reported in the abstract
Hazard ratio
0.79
P = 0.067
Observational data: associations, not effects.
Further findings
| Outcome | HR | P value |
|---|---|---|
| Acute myocardial infarction · 6 monthsSignificantly lower risk with SGLT2 inhibitors | 0.69 | P = 0.043 |
| All-cause hospitalization/emergency room visits · 6 monthsSignificantly lower risk with SGLT2 inhibitors | 0.69 | P < 0.001 |
| All-cause hospitalizations · 1 year | 0.73 | P < 0.001 |
Primary and individual endpoints · 1 year
- No significant differences except for all-cause hospitalizations and urinary tract infections
Safety
| Outcome | HR | P value |
|---|---|---|
| Urinary tract infections · 1 year | 0.77 | P = 0.009 |
Original publication
Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement. JACC Adv. Published 17 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →